SUNNYVALE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Dionex Corporation (NASDAQ:DNEX) today announced record sales and earnings per share for its full year and fourth quarter of fiscal 2005.
Sales for the fiscal year ended June 30, 2005, were $279.3 million, an increase of 8%, compared with the $258.8 million reported for the last fiscal year. Excluding the favorable effects of currency fluctuations, sales grew by 4% for the year. Diluted earnings per share for the year were $2.13, an increase of 13% over the $1.89 reported last year. Gross profit and operating income margins were strong at 67.0% and 23.2%, respectively. Cash flow from operations was very strong, totaling approximately $57 million for the year.
For the fourth quarter ended June 30, 2005, sales were $71.2 million, an increase of 3%, compared with the $69.3 million reported in the fourth quarter of last year. Excluding the favorable effects of currency fluctuations, sales grew by 1% for the quarter. Diluted earnings per share for the quarter were $.53, an increase of 8%, compared with the $.49 reported for the same quarter last year. Cash flow from operations for the quarter was very strong, totaling over $19 million.
During the fourth quarter, the Company repurchased 588,400 shares of its common stock, bringing the total shares repurchased for the year to 1,355,900 shares. In fiscal 2004, the Company repurchased 1,116,300 shares of its common stock.
Lukas Braunschweiler, President and Chief Executive Officer, commenting on the results, said, "We finished the year with a solid fourth quarter, meeting our expectations. These fourth quarter results add to the strong results reported for the first three quarters, bringing our sales and earnings per share for the full year to the highest levels in the history of the Company.
"Excluding an incremental $3 million of nonrecurring sales in the fourth quarter of fiscal 2004 related to the new drinking water analysis regulations enacted in Japan last year, sales grew by 7% in the fourth quarter. Excluding the total $8 million of nonrecurring revenue reported in Japan for fiscal 2004, sales grew by 11% for the full fiscal year 2005.
"Sales in North America grew in the mid-single digits for the year, showing a positive trend in the fourth quarter. Sales in Europe grew mid- teens for both the quarter and the year. Sales in Japan were up slightly in the fiscal year when excluding the $8 million in incremental revenues related to the new drinking water regulations enacted in Japan in fiscal 2004. Sales in Asia/Pacific outside of Japan continued to grow strongly in the double digits, driven by strong business in China, Korea, Australia and India.
"Sales in our Life Sciences market were up slightly in the quarter and in the full fiscal year. Our Environmental market was down slightly due to the nonrecurring sales in Japan in fiscal 2004. Sales in our Chemical/Petrochemical and Food/Beverage markets were up in both the fourth quarter and the year. The softness in our Life Sciences business was mainly due to slower project spending at some of our larger pharmaceutical customers, though we observed a more positive trend towards the end of our fourth quarter.
"We also saw good growth in both ion chromatography and HPLC in fiscal 2005, with our ion chromatography products growing in the high single digits and our analytical flow HPLC products growing over 20%. The new high-end ICS- 3000 RFIC ion chromatography and the new UltiMate 3000 nano/micro flow HPLC systems launched at the 2005 Pittsburgh Conference in late February have been well received by our customers and already contributed significantly to our fourth quarter results.
"Going into fiscal year 2006, Dionex will adopt SFAS 123R, the Financial Accounting Standard Board's newly revised accounting standard for stock-based compensation. After careful consideration of various alternatives, we decided to continue with our strategy of using stock options as our long-term incentive and compensation vehicle. We believe stock options, provide the best balanced approach for both employees and our shareholders. Under our stock option program going forward, we plan to have a reduced annual option grant rate corresponding to an average of approximately 1.5% of our total shares outstanding. We forecast that our projected levels of grants will have a pre-tax expense impact of approximately 2% of our annual sales going forward.
"We believe that we are well-positioned for solid growth in fiscal 2006. Looking at the first quarter, we estimate that sales will be in the range of $66.0-$68.0 million and that GAAP diluted earnings per share will be in the range of $0.42-$0.44. For the entire year, we estimate that sales will be in the range of $294-$302 million and GAAP diluted earnings per share will be in the range of $2.12-$2.18. Excluding the projected option expense charges related to the adoption of SFAS 123R, our EPS will be in the range of $0.47- $0.49 for the first quarter and in the range of $2.32-$2.38 for the full year. These estimates are based on the following assumptions: (a) continued slight improvements in the economies of the U.S., Europe and Japan; (b) the demand from our pharmaceutical customers will improve in the second half of the fiscal year from the levels observed in calendar year 2005 so far; (c) foreign currency rates will not have a significant impact in fiscal 2006." Dionex Corporation is a leading manufacturer and marketer of chromatography systems for chemical analysis. The Company's systems are used in environmental analysis and by the life sciences, food and beverage, chemicals, petrochemicals, power generation and electronics industries in a variety of applications.
The company will discuss fourth quarter results in a conference call on Thursday, August 4, 2005 at 1:30 p.m. Pacific Time (PT). To listen to the call live, please turn into the webcast via http://www.dionex.com/. A playback of the conference call will be available from 8:00 a.m. PT, Friday, August 5, 2005 until 5:00 p.m. PT, Friday, September 30, 2005.
Certain statements regarding sales and earnings contained herein that are not purely historical are forward-looking statements. Factors that may affect sales and earnings causing actual results to differ from these statements are foreign currency fluctuations, competition from other products, economic conditions in the areas in which the company sells its products, and existing product obsolescence. These factors and other risk and uncertainties are discussed in greater detail in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.
DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
(Unaudited) Three Months Ended Twelve Months Ended
June 30, June 30,
2005 2004 2005 2004 Net sales $71,156 $69,273 $279,317 $258,834
Cost of sales 22,564 24,470 91,754 88,944
Gross profit 48,592 44,803 187,563 169,890 Operating expenses:
Selling, general and
administrative 28,644 23,671 102,539 89,100
Research and product
development 5,227 4,951 20,354 19,155
Total operating
expenses 33,871 28,622 122,893 108,255 Operating income 14,721 16,181 64,670 61,635 Interest income, net 346 201 1,100 561
Other income (expense) 421 (72) 801 (340) Income before taxes on
income 15,488 16,310 66,571 61,856
Taxes on income 4,349 5,678 21,081 20,481
Net income $11,139 $10,632 $45,490 $41,375 Basic earnings per share $0.55 $0.51 $2.20 $1.96
Diluted earnings per share $0.53 $0.49 $2.13 $1.89
Shares used in computing
per share amounts:
Basic 20,357 20,897 20,655 21,056
Diluted 20,868 21,822 21,388 21,943
DIONEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
AT JUNE 30, 2005 AND JUNE 30, 2004
(In thousands)
(Unaudited) June 30, June 30,
2005 2004
ASSETS Current assets:
Cash, cash equivalents and short
term investments $53,781 $58,786
Accounts receivable, net 55,450 53,128
Inventories 26,510 24,838
Other current assets 16,342 14,168 Total current assets 152,083 150,920 Property, plant and equipment, net 53,914 46,656
Goodwill and other intangible
assets, net 27,556 29,032
Other assets 4,600 8,857
$238,153 $235,465 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:
Notes payable $-- $1,468
Accounts payable 10,031 8,113
Accrued liabilities 34,939 31,822
Income taxes payable 1,593 2,214
Accrued product warranty 3,514 3,584 Total current liabilities 50,077 47,201 Deferred income taxes and other 6,305 4,810
Stockholders' equity 181,771 183,454
$238,153 $235,465
DATASOURCE: Dionex Corporation CONTACT: Craig McCollam of Dionex Corporation, +1-408-481-4107 Web site: http://www.dionex.com/
|